ArticleScientific reports2025
A geminivirus attenuation vector for crop protection using episomal plant gene therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of efficient geminivirus-derived LIR-elements for exogenous protein expression.Archives of virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Although plant viruses inflict billions of dollars in global crop yield loss, they also encode functions that can be used for crop protection. A viral vector attenuation strategy is developed that enables modulation of a 'gene therapy' viral vector designed for protective gene delivery. This attenuation vector targets its homologous native viral counterpart, where the A-component of the bipartite tomato mottle virus (ToMoV) viral vector delivers siRNA constructs targeting native viral sequences for which its own genome has been synthetically modified to avoid silencing. A target coat protein replacement viral vector was engineered with a Nano-luciferase reporter gene to quantify effectiveness based on bioluminescence. To silence the target virus, siRNA constructs were designed against the transactivating protein (TrAP) which is responsible for activating the promoter driving the native coat protein transcript. This siRNA was placed in the attenuation vector designed to avoid self-targeting by modifying its own TrAP sequence. Viral infections were initiated in tobacco using Agrobacterium DNA delivery. Measurements at 3, 6, and 9 days post infiltration revealed a significantly reduced luminescence in attenuation treatment demonstrating suppression of the target virus transgene expression. This work sets the stage for a breadth of virus attenuation studies that can be rapidly applied to diverse crop threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.